When was Neurocrine founded?

Neurocrine was founded in 1992 and raised its 1st funding round 17 years after it was founded.

Where is Neurocrine located?

Neurocrine is headquartered in San Diego, United States.

How many employees does Neurocrine have?

As of Aug 31, 2026, the latest employee count at Neurocrine is 2455.

Is Neurocrine a funded company?

Neurocrine is a funded company, having raised a total of $10M across 4 funding rounds to date. The company's 1st funding round was a $***** PE round, raised on Dec 17, 2009.

How much is Neurocrine worth?

The last known valuation of Neurocrine was $***** as of Jan 08, 2026.

When was the latest funding round of Neurocrine?

Neurocrine's latest funding was a $***** Post IPO round on Aug 05, 2023, with participation from 1 investor.

What is the annual revenue of Neurocrine?

Annual revenue of Neurocrine is more than $1B as on Dec 31, 2025

Where does Neurocrine rank among its competitors?

Neurocrine ranks 27th amongst 2895 active competitors, of which 977 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Neurocrine?

Neurocrine's top competitors include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Neurocrine - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of small molecule therapeutics for endocrine and CNS disorders. The company's product line include elagolix, a gonadotropin-releasing hormone antagonist for endometriosis and uterine leiomyoma, and NBI-98854 a vesicular monoamine transporter 2 inhibitor for the treatment of movement disorders.

Key Metrics

Founded Year

1992

Location

San Diego, United States

Stage

Acquired

Total Funding

$10M in 4 rounds

Latest Funding Round

Post IPO, Aug 05, 2023, $*****

Last Known Valuation

$***** as on Jan 08, 2026

Investors

Venrock & 7 more

Ranked

27^th among 2895 active competitors

Annual Revenue

$1B+ as on Dec 31, 2025

Employee Count

2,455 as on Aug 31, 2026

Investment & Acquisitions

Soleno & 2 more

Similar Companies

Jazz Pharmaceuticals & 614 more

Exit Details

Acquired by Immedica (Jan 08, 2026)

View Neurocrine's full profile

Neurocrine is associated with 4 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Neurocrine Biosciences, Inc. CIN: 5056220 , United States, Active	Dec 21, 2016	-	-	-
Neurocrine Biosciences Inc CIN: 914475 , United States, Active	Mar 19, 1996	$1B+ (As on Dec 31, 2025)	1400 (As on Dec 31, 2023)	-
NEUROCRINE BIOSCIENCES, INC. CIN: 33-0525145 , United States, Active	Mar 19, 1996	-	900 (As on Dec 31, 2021)	-
Neurocrine Biosciences, Inc. CIN: 330525145 , United States, Active	Dec 31, 1999	-	1768 (As on Dec 31, 2024)	-

Neurocrine got acquired by Immedica on Jan 08, 2026.

Click here to take a look at Neurocrine's acquisition in detail

Neurocrine has raised a total funding of $10M over 4 rounds. Its first funding round was on Dec 17, 2009. Its latest funding round was a Post IPO round on Aug 05, 2023 for $*****. 1 investor participated in its latest round. Neurocrine has 8 institutional investors.

Here is the list of recent funding rounds of Neurocrine:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 05, 2023	4098141	Post IPO	6799716	6467867	7232492	7023400
Mar 20, 2019	8754430	Post IPO	9578174	1797027	1360425	BB Biotech
Apr 2017	3650104	Post IPO	5000993	7687123	1276804	8091411

Access funding benchmarks and valuations. Sign up today!

View details of Neurocrine's funding rounds and investors

Neurocrine's employee count trend

Neurocrine has 2,455 employees as of Aug 26. Here is Neurocrine's employee count trend over the years:

Uncover Neurocrine's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Neurocrine include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Here is the list of Top 10 competitors of Neurocrine, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
3rd	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
4th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
5th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
9th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
10th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
27th	Neurocrine 1992, San Diego (United States), Acquired	Developer of small molecule therapeutics for endocrine and CNS disorders	$10M	Venrock, BB Biotech & 6 others	68/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Neurocrine's competitors? Click here to see the top ones

Neurocrine has made 1 investment in Voyager Therapeutics and acquired Soleno and Diurnal.

Here is the list of these investments and acquisitions:

Date of Investment/Acquisition	Type	Company Name	Founded Year	Location
Apr 06, 2026	Acquisition	Soleno	1999	Redwood City (United States)
Aug 30, 2022	Acquisition	Diurnal	2004	Cardiff (United Kingdom)
Jan 29, 2019	Investments	Voyager Therapeutics	2014	Cambridge (United States)